Ignite Creation Date:
2024-05-11 @ 8:31 AM
Last Modification Date:
2024-10-26 @ 3:28 PM
Study NCT ID:
NCT06401044
Status:
RECRUITING
Last Update Posted:
2024-07-03
First Post:
2024-05-02
Brief Title:
A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease
Sponsor:
Amgen
Organization:
Amgen
Study Overview
Official Title:
A Phase 12 Randomized Double-Masked Placebo-Controlled Multicenter Study to Assess the Safety Pharmacokinetics and Efficacy of AMG 732 in Healthy Subjects and Subjects With Moderate-to-Severe Active Thyroid Eye Disease
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of this study is to investigate the safety and tolerability of AMG 732 after single subcutaneous SC doses
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None